

May 21, 2026

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

This is to inform that on May 20, 2026, AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization, Directorate General of Health Services, Government of India to import for sale and distribution of Acalabrutinib maleate tablets 100 mg (Brand name: Calquence[®]) for an additional indication.

Through this approval, Acalabrutinib in combination with Bendamustine and Rituximab (BR) is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant (ASCT).

The receipt of this permission paves way for the marketing of Acalabrutinib maleate tablets 100 mg (Brand name: Calquence[®]) in India for the specified additional indication, subject to the receipt of related statutory approvals, if any.

We request you to take the above intimation on record.

Thanking you,

For AstraZeneca Pharma India Limited

Tanya Sanish

Company Secretary & Compliance Officer